Video wird geladen...

Video konnte nicht geladen werden

Zur Startseite

#Cybin reports #breakthrough Phase 2 data for #CYB003 in Major Depressive Disorder (#MDD), with 100% of patients responsive to treatment and 71% in remission at 12 months after just two 16mg doses. Learn more: #Neuropsychiatry #MentalHealth #Depression

9 Kommentare

Profilbild von Psych Investor
Psych Investorvor 1 Jahr

👏👏

Profilbild von SportsFanatic
SportsFanaticvor 1 Jahr

Incredible!! Congrats to you and the entire team!!!! 👏🏼👏🏼👏🏼

Profilbild von Dream State Awake
Dream State Awakevor 1 Jahr

Big pharma won't like this.

Profilbild von Minimoose
Minimoosevor 1 Jahr

Nice! Keep on Moosin' on

Profilbild von Altered Updates
Altered Updatesvor 1 Jahr

👏

Profilbild von Aurora
Auroravor 1 Jahr

Disappointing to see Cybin partnering with Paul Joseph Watson, who famously said "depression is nothing more than dissatisfaction with life, it's temporary unhappiness." .

Profilbild von B.Smith
B.Smithvor 1 Jahr

👌

Profilbild von A Rocket
A Rocketvor 1 Jahr

Not so much of a breakthrough when all companies report the same data. No competitive differentiation is possible and all psychedelics substitute for one another. Zero alpha. Returns trend to the mean. Next.

Profilbild von eli.bda
eli.bdavor 1 Jahr

Let cybin coooooook

Ähnliche Videos

Today we’re reporting interim Phase 1 clinical data for our REC-617 monotherapy trial – with plans to expand into combination studies in advanced solid tumors. At the AACR Special Conference in Cancer Research, CSO David Hallett shared interim monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. 🔹The interim Phase 1 clinical data for REC-617 included: ▫️Dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagement; ▫️Confirmed partial response (PR) during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in an advanced setting, with durable response ongoing after more than 6 months of treatment; ▫️In 4 additional patients, a best response of stable disease (SD) for up to 6 months of treatment. Dr. Hallett noted: “Cell cycle dysregulation and transcriptional 'addiction' are both hallmarks of many aggressive cancers. By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index.” "These initial findings for REC-617 represent an exciting step forward in the development of CDK7 inhibitors, with a favorable PK/PD profile and a durable confirmed partial response observed in dose escalation in a highly pre-treated patient population," said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer. “Designed using our AI-powered OS platform, REC-617 reflects our focus on enhancing the therapeutic index to deliver more effective and safer treatment options for patients. We are eager to continue this momentum in dose escalation and to initiate the next phase of the program next year." 👉Learn more: 🔹Join the Update Call: Tomorrow, Tues., Dec. 10 at 8:30am ET, Dr. Hallett and Dr. Khan will hold a live Update Call webcast to present the preliminary data. ▫️Submit questions for the Update Call here: ▫️Tune in to the Update Call here on X or on: LinkedIn: YouTube:

Recursion

11,879 Aufrufe • vor 1 Jahr